Evommune Announces Top Line Data from Phase 2 Trial of EVO756 in Chronic Inducible Urticaria Demonstrating Robust Activity and Favorable Safety Profile May 28, 2025
HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics’ investigational novel conditionally activated IL-2 pro-drug WTX-124 May 27, 2025
Rectify Pharma to Present Translational Data on Novel Approach to Treat Chronic Kidney Disease and Vascular Calcification at ERA 2025 May 27, 2025
Be Biopharma Announces New Preclinical Data for BE-102, a B Cell Medicine for the Potential Treatment of Hypophosphatasia May 19, 2025
TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update May 13, 2025
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update May 13, 2025
